miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma.
Animals
Cell Line, Tumor
Cell Proliferation
/ genetics
Doxycycline
/ pharmacology
Focal Adhesion Kinase 1
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Integrins
/ genetics
Mice, SCID
MicroRNAs
/ genetics
Phosphorylation
RNA, Small Interfering
Rhabdomyosarcoma
/ drug therapy
Xenograft Model Antitumor Assays
ITGA9
Integrins
Pediatric cancer
Rhabdomyosarcoma
miRNA
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
09
09
2019
revised:
16
01
2020
accepted:
27
02
2020
pubmed:
7
3
2020
medline:
31
12
2020
entrez:
7
3
2020
Statut:
ppublish
Résumé
The prognosis of patients with metastatic rhabdomyosarcoma (RMS), the most common type of soft tissue sarcoma in children, is poor and no strategies have been identified to improve their dismal prognosis. Alpha-9 integrin (ITGA9) plays a particularly crucial role in cancer progression and invasiveness. Despite the consensus on the remarkable pro-oncogenic potential of this protein, the miRNA-mediated regulation of ITGA9 has barely been studied to date. In the present study, miR-7 and miR-324-5p were selected as the best candidates after a screening to find ITGA9 regulators, and their effects on cell proliferation and invasion in RMS are described and characterized for the first time. Interestingly, the overexpression of both miRNA produced a clear impairment of cell proliferation, while miR-7 also induced a remarkable drop in cell invasion. Furthermore, the stable overexpression of both miRNA was found to reduce tumor growth in orthotopic RMS models and miR-7 was able to impair metastatic lung colonization. Consequently, we conclude that miR-7 and miR-324-5p show anti-oncogenic and anti-metastatic potential, thereby opening up the possibility of being used as novel therapeutic tools to avoid RMS progression.
Identifiants
pubmed: 32142919
pii: S0304-3835(20)30104-X
doi: 10.1016/j.canlet.2020.02.035
pii:
doi:
Substances chimiques
ITGA9 protein, human
0
Integrins
0
MIRN324 microRNA, human
0
MIRN7 microRNA, human
0
MicroRNAs
0
RNA, Small Interfering
0
Focal Adhesion Kinase 1
EC 2.7.10.2
PTK2 protein, human
EC 2.7.10.2
Doxycycline
N12000U13O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-59Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there is no conflict of interest regarding the publication of this paper.